No Data
PW MEDTECH (01358): SiChuan RuiJian Medical's net profit attributable to the parent for the first quarter is approximately 36.1711 million yuan, a year-on-year increase of 15.68%.
PW MEDTECH (01358) announced the first quarter performance of SiChuan RuiJian Medical for 2025, with revenue of approximately 0.145 billion yuan, ...
PW MEDTECH: ANNUAL REPORT 2024
The industry is hotly discussing the future trends of nuclear medicine, will Hybrid NewCo become a new model for the RDC Industry to venture abroad? | Industry Observation
① Today, the 2025 Future XDC New Drug Conference is held in Chengdu; ② Executives from companies such as Baillie Tianheng and Kelun Botai, along with numerous experts and scholars in the industry, will jointly discuss cutting-edge technologies in ADC/nuclear drug development, overseas strategies, and other Topics.
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
PW MEDTECH (01358.HK) reported a 1.6% decrease in annual profit attributable to shareholders to 0.151 billion yuan, with a final dividend of 5.3 Hong Kong cents.
On March 29, Glonghui reported that PW MEDTECH (01358.HK) announced its annual performance, with revenue rising by 13.9% to approximately RMB 0.769 billion for the year ending December 31, 2024; gross profit increased by 10.1% to approximately RMB 0.419 billion; profit attributable to owners of the company decreased by 1.6% to approximately RMB 0.151 billion, with basic earnings per share at RMB 9.77 cents, and a proposed final dividend of HKD 5.3 cents per share.